New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 13, 2014
07:09 EDTEBSEmergent BioSolutions sees FY13 revenue $311M-$313M, consensus $307.84M.
The company also anticipates FY13 GAAP net income of $30M-$32M. Excluding approximately $7M of transaction-related and restructuring costs incurred during the year, the company is providing a forecast for 2013 non-GAAP adjusted net income of $35M-$37M.
News For EBS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 25, 2015
07:08 EDTEBSEmergent BioSolutions receives FDA approval of Anthrasil
Emergent BioSolutions announced that the FDA has approved Anthrasil, Anthrax Immune Globulin Intravenous, also known as AIGIV, for treatment of inhalational anthrax in combination with appropriate antibacterial drugs. Achievement of this milestone triggers a $7M payment to the company under a development contract with the Biomedical Advanced Research and Development Authority. Anthrasil has received Orphan Drug designation and as a result of this approval, the product qualifies for seven years of market exclusivity.
March 24, 2015
07:13 EDTEBSEmergent BioSolutions awarded $31M contract for advanced development of NuThrax
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use